ENMD-1198 Reduces Tumor Growth in Liver Cancer
Author Information
Author(s): Christian Moser, Sven A. Lang, Akira Mori, Claus Hellerbrand, Hans J. Schlitt, Edward K. Geissler, William E. Fogler, Oliver Stoeltzing
Primary Institution: Regensburg Medical Center, Regensburg, Germany
Hypothesis
Therapeutic inhibition of HIF-1α could be achieved by using a novel tubulin-binding agent (ENMD-1198).
Conclusion
ENMD-1198 effectively inhibits HIF-1α and STAT3 in human HCC cells, leading to reduced tumor growth and vascularization in vivo.
Supporting Evidence
- ENMD-1198 inhibited the phosphorylation of MAPK/Erk, PI-3K/Akt, and FAK.
- Activation of HIF-1α and STAT3 was dramatically reduced by ENMD-1198.
- Tumor cell migratory and invasive properties were significantly inhibited.
- In vivo, treatment with ENMD-1198 led to a significant reduction in tumor growth and vascularization.
Takeaway
A new drug called ENMD-1198 helps stop liver cancer from growing by blocking certain signals that help tumors grow.
Methodology
The study used human HCC cell lines and in vivo tumor models to evaluate the effects of ENMD-1198 on cell signaling, migration, and tumor growth.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website